VasoGenix, Cleveland Clinic to develop heart study

By Elaine Rigoli

Tampa, Fla., May 15 - VasoGenix Pharmaceuticals, Inc. has entered into an agreement with Cleveland Clinic to develop VasoGenix's first drug, calcitonin gene-related peptide for the treatment of heart failure.

The clinic will prepare a clinical protocol design for a phase 1/2 trial to be conducted at the clinic and coordinated by the Cleveland Clinic Cardiovascular Coordinating Center, according to a news release.

Calcitonin gene-related peptide is distributed in neural tissue throughout the human body but concentrated in the heart, where nerves secrete it following a heart attack in an attempt to reduce the infarct size and keep heart cells alive, the release said.

VasoGenix Pharmaceuticals is a Lenexa, Kan.-based biopharmaceutical company focused on developing cardiovascular drugs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.